

Docket (/docket/FDA-2022-N-2810) / Document (FDA-2022-N-2810-0001) (/document/FDA-2022-N-2810-0001)  
/ Comment



## Comment from Health Watch USA

Posted by the **Food and Drug Administration** on Jun 13, 2023

View More Comments 20.92K (/document/FDA-2022-N-2810-0001/comment)

View Related Comments 20.92K (/docket/FDA-2022-N-2810/comments)

Share ▾

Comment

Another important reason for updating the COVID-19 vaccine's formulation is the mounting evidence of significant immunological imprinting which occurs with SARS-CoV-2 or vaccine exposure. In other words, your first exposure to the virus shapes your immunological response to all future exposures.

This was evident from the data presented at the Sept. 1, 2022, ACIP meeting where all animals were vaccinated with the original SARS-CoV-2 strain, and then had a robust response to the original viral strain with the Monovalent BA4/5 booster. In addition, booster efficacy data from a number of other studies showed, what some would describe, as a less than expected advantage of the bivalent booster over the original booster.

Thus, it would appear advantageous to administer to SARS-CoV-2 immunologically naive individuals, such as young children, the most immunologically diverse and up-to-date vaccine possible.

I would like to encourage the committee to approve the administration of the current SARS-CoV-2 bivalent formulation to young children and to update this formulation on a regular basis.

Attachments 1



Comment from Health Watch USA

More Information ▾



Download (https://downloads.regulations.gov/FDA-2022-N-2810-20741/attachment\_1.pdf)

**Comment ID**

FDA-2022-N-2810-20741

**Tracking Number**

ldb-sidd-rrf8

**Comment Details****Submitter Info****Document Subtype**

Electronic Regulation from Form

**Received Date**

Jan 25, 2023

*Your Voice in Federal Decision Making*

[About \(/about\)](#) [Bulk Data Download \(/bulkdownload\)](#) [Agencies \(/agencies\)](#) [Learn \(/learn\)](#)

[Reports \(https://resources.regulations.gov/public/component/main?main=Reports\)](#) [FAQ \(/faq\)](#)

[Privacy & Security Notice \(/privacy-notice\)](#) | [User Notice \(/user-notice\)](#) |  
[Accessibility Statement \(/accessibility\)](#) | [Developers \(https://open.gsa.gov/api/regulationsgov/\)](https://open.gsa.gov/api/regulationsgov/) |  
[FOIA \(https://www.gsa.gov/reference/freedom-of-information-act-foia\)](https://www.gsa.gov/reference/freedom-of-information-act-foia)

[Support \(/support\)](#) [Provide Site Feedback](#)